Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Deseret News Utah Index
Deseret News Composite
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Clovis Oncology Inc
(NQ:
CLVS
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Dec 20, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Clovis Oncology Inc
< Previous
1
2
3
4
5
6
7
Next >
50 Stocks Moving In Wednesday's Mid-Day Session
May 04, 2022
Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares jumped 51.7% to $2.0180 after gaining around 5% on Tuesday. Sharps Technology, Inc. (NASDAQ: STSS) rose 31.4% to $1.6815 after...
Via
Benzinga
Clovis Oncology: Q1 Earnings Insights
May 04, 2022
Clovis Oncology (NASDAQ:CLVS) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Clovis Oncology Announces First Quarter 2022 Operating Results and Provides Update on Clinical Development Programs
May 04, 2022
From
Clovis Oncology, Inc.
Via
Business Wire
Clovis Oncology's Rubraca Significantly Improves PFS In Ovarian Cancer Regardless Of Biomarker Status
March 31, 2022
Via
Benzinga
HER2-Targeted Therapies Introduced Early in Breast Cancer Treatment Offering Hope for Patients
May 04, 2022
Palm Beach, FL – May 4, 2022 – FinancialNewsMedia.com News Commentary – Globally, the R&D on breast cancer in all its forms has been steadily growing at a significant pace over the last several years...
Via
FinancialNewsMedia
Exposures
COVID-19
Clovis Oncology Highlights Rubraca® (Rucaparib) and FAP-2286 Data to be Presented at 2022 ASCO Annual Meeting
April 28, 2022
From
Clovis Oncology, Inc.
Via
Business Wire
Advanced Immunological and Clinical Trials for Treating Ovarian Cancer Accelerating
April 25, 2022
Palm Beach, FL – April 25, 2022 – FinancialNewsMedia.com News Commentary – The formation of mutational cells or tissues in female reproductive organs called ovaries leads to ovarian cancer. Cancer...
Via
FinancialNewsMedia
Topics
Intellectual Property
Exposures
Intellectual Property
Clovis Oncology Q1 2022 Earnings Conference Call On May 4, 2022 At 08:30 AM ET
April 25, 2022
Clovis Oncology (NASDAQ:CLVS) will host a conference call at 08:30 AM ET on May 4, 2022, to discuss Q1 2022 earnings results. How to Attend Clovis Oncology (CLVS) Conference Call Follow this link to...
Via
Benzinga
Clovis Oncology to Announce First Quarter 2022 Financial Results and Host Webcast Conference Call on May 4
April 20, 2022
From
Clovis Oncology, Inc.
Via
Business Wire
Advancements of CAR-T Cell Therapies Importance Grows While Cancer Cases Increasing
April 14, 2022
Palm Beach, FL – April 14, 2022 – FinancialNewsMedia.com News Commentary – CAR-T therapy is a sort of treatment in which a patient’s T cells which is a type of immune system cell, are genetically...
Via
FinancialNewsMedia
Clovis Oncology Targeted Cancer Radiation Therapy Shows Greater Tumor Inhibition
April 08, 2022
Clovis Oncology Inc (NASDAQ: CLVS) announced two abstracts featuring
Via
Benzinga
Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022
April 08, 2022
From
Clovis Oncology, Inc.
Via
Business Wire
68 Biggest Movers From Yesterday
April 05, 2022
Gainers GBS Inc. (NASDAQ: GBS) jumped 68% to settle at $1.31 on Monday. Zacks Small-Cap Research issued a note on GBS with an $8 valuation. Aterian, Inc. (NASDAQ: ATER) shares...
Via
Benzinga
35 Stocks Moving In Monday's Mid-Day Session
April 04, 2022
Gainers Aterian, Inc. (NASDAQ: ATER) shares jumped 43.5% to $3.3457. Aterian said Cynthia Williams has joined the Company's Board of Directors. Jumia Technologies AG (...
Via
Benzinga
55 Biggest Movers From Friday
April 04, 2022
Gainers Takung Art Co., Ltd. (NASDAQ: TKAT) surged 61.8% to close at $3.64 on Friday. Chicken Soup for the Soul Entertainment, Inc. (NASDAQ: CSSE) rose 43.8% to settle at $11.49...
Via
Benzinga
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
April 03, 2022
Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that...
Via
Benzinga
53 Biggest Movers From Yesterday
April 01, 2022
Gainers Longeveron Inc. (NASDAQ: LGVN) shares jumped 105.4% to close at $13.80 on Thursday after the company announced the publication of results from a Phase 1 trial testing...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
March 31, 2022
Gainers Longeveron (NASDAQ:LGVN) stock rose 60.6% to $10.79 during Thursday's regular session. As of 13:31 EST, this security is trading at a volume of 84.1 million...
Via
Benzinga
AMD Stock Downgrade: Why Barclay’s Thinks the Chip Company Is Headed Lower
March 31, 2022
Advanced Micro Devices (AMD) stock is slipping on Thursday as investors react to a downgrade from Barclays analyst Blayne Curtis.
Via
InvestorPlace
Clovis Oncology News: Why CLVS Stock Is Roaring Higher Today
March 31, 2022
Clovis Oncology (CLVS) stock is in the news Thursday as shares rocket higher thanks to positive data from a recent clinical trial.
Via
InvestorPlace
Why Clovis Oncology Stock Is Soaring Today
March 31, 2022
Clovis Oncology Inc (NASDAQ: CLVS) is trading higher Thursday morning after the company announced data from the monotherapy arm of the ATHENA trial achieved the primary...
Via
Benzinga
The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall
March 31, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
March 31, 2022
Rise and shine, trader! We're getting ready for another busy day of trading with the biggest pre-market stock movers for Thursday!
Via
InvestorPlace
Clovis Oncology’s Rubraca® (Rucaparib) Significantly Improves Progression-Free Survival in First-line Maintenance Treatment in Women with Ovarian Cancer Regardless of Their Biomarker Status in Phase 3 ATHENA-MONO Trial
March 31, 2022
From
Clovis Oncology, Inc.
Via
Business Wire
Clovis Oncology and Evergreen Theragnostics Initiate Development and Manufacturing Services Agreement for Actinium-225-Labeled FAP-2286
March 16, 2022
From
Clovis Oncology, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
February 25, 2022
Gainers Surgalign Holdings (NASDAQ:SRGA) ...
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
March 16, 2022
On Wednesday, 90 companies set new 52-week lows. Areas of Significance In Today's 52-Week Lows: The company with the largest market cap to set a new 52-week low was...
Via
Benzinga
Clovis Oncology Highlights Ongoing Phase 1/2 LuMIERE Clinical Study and Multi-Tumor Imaging Investigator-Initiated Trial of FAP-2286 Fibroblast Activation Protein-Targeted Radiotherapy Candidate at an Upcoming Nuclear Medicine Meeting
February 25, 2022
From
Clovis Oncology, Inc.
Via
Business Wire
88 Biggest Movers From Yesterday
February 25, 2022
Gainers Cyren Ltd. (NASDAQ: CYRN) shares surged 118.9% to settle at $4.75 on Thursday. Cyren recently announced a $12 million private placement. Indonesia Energy Corporation...
Via
Benzinga
Clovis Oncology Announces 2021 Operating Results and Anticipated 2022 Development Milestones
February 23, 2022
From
Clovis Oncology, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.